Business, energy, technology, markets and global industry news from Business News Today

Skip to content

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

AB-10-8008

PharmaDeviceNews AB-10-8008

Representative image: Laboratory researchers handle blood samples during chronic hepatitis B drug development, reflecting Brii Bio’s Phase 2b ENRICH and ENHANCE results for BRII-179, elebsiran and pegylated interferon alfa.

Pharma & Biotech

Could 16 weeks of AHB-137 change hepatitis B treatment? AusperBio reveals 15-month durability

by Pallavi Madhiraju
November 6, 2026
0 Comments

AusperBio reports AHB-137 functional cure lasting up to 15 months off hepatitis B treatment, with larger trials needed to confirm durability.

Read More

Latest news and features

What does Natera’s leadership change mean for Signatera and precision oncology?
Nimbus Therapeutics matches established arthritis drugs in mice, but can SIK2 inhibition work in patients?
Biocodex’s €15m microbiome investment targets a major drug manufacturing bottleneck
Brii Bio’s hepatitis B strategy delivers 32.4% sustained HBsAg loss, but can it reach Phase 3?
Could 16 weeks of AHB-137 change hepatitis B treatment? AusperBio reveals 15-month durability
Antengene’s US$1.2bn UCB deal enters human testing, but can ATG-201 control autoimmune disease?
Gilead Sciences’ Livdelzi achieves 75% ALP normalisation response in Phase 3 IDEAL trial
Vir Biotechnology’s ECLIPSE-1 data arrive Sunday. Can monthly therapy challenge Hepcludex?
Ellipsis Health buys Kouper Health, but can AI finally close the gaps between patient visits?
FX Shoulder Solutions brings stemless reverse shoulder replacement to the US, but is the evidence ready?
Rybrevant Faspro shrank tumours in 42% of patients, but can Johnson & Johnson prove survival benefit?
Ivonescimab clears half of lung tumours before surgery, but can Akeso prove lasting benefit?

POPULAR NEWS

plated Skin Science’s new BODY Serum brings platelet-derived exosome skincare beyond the face, targeting signs of aging, texture and hydration across the body. Representative image.

Pharma & Biotech

Rion Aesthetics expands plated Skin Science exosome platform with $338 BODY Serum

August 19, 2026

Pharma & Biotech

Omabit raises $2m to connect fragmented clinical evidence, but can AI improve drug development decisions?

October 27, 2026

Medical Devices & Diagnostics

Presage Technologies SmartSpectra cleared for contactless vital signs monitoring

July 8, 2026

Latest business and industry news

TC Energy approves C$3bn pipeline projects as AI power demand drives gas expansion
Cloudflare revenue jumps 39% to $782.5m, but GAAP losses raise a bigger question
US expands Cuba sanctions to technology, shipping and manufacturing sectors
Freeport-McMoRan (FCX) approves $4.5bn copper expansion as shares fall 7.5%
Adani Ports (ADANIPORTS) targets Evos in €2.56bn deal, but can debt-funded expansion deliver returns?

TAGS

AstraZeneca clinical trials Eli Lilly and Company European Medicines Agency FDA immunotherapy Inc. Johnson & Johnson medical devices non-small cell lung cancer oncology precision oncology U.S. Food and Drug Administration United States Food and Drug Administration US Food and Drug Administration

About PharmaDeviceNews
Disclaimer
Editorial Policy
Privacy Policy
Contact Us

© 2026 PharmaDeviceNews.com. All rights reserved.